{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    9,
    10,
    11,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    26,
    27,
    28
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Pembrolizumab Arm",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Pembrolizumab (MK-3475) 200 mg IV every 3-weeks (Q3W) for up to 35 administrations (approx. 2 years)."
      },
      {
        "id": "arm_2",
        "name": "Physicians’ Choice Arm",
        "type": {
          "code": "Active Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Active Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Investigator’s choice of one of three regimens: Paclitaxel (80-100 mg/m2 on Days 1, 8, 15 of 28-day cycle), Docetaxel (75 mg/m2 Q3W), or Irinotecan (180 mg/m2 Q2W)."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_1",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_1",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_7",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_7"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_8",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_8"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_9",
        "armId": "arm_2",
        "epochId": "epoch_4",
        "elementIds": [
          "elem_9"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_10",
        "armId": "arm_2",
        "epochId": "epoch_5",
        "elementIds": [
          "elem_10"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [
      {
        "id": "cohort_1",
        "name": "Global Cohort",
        "instanceType": "StudyCohort",
        "characteristic": "Approximately 600 subjects enrolled globally (including China during global enrollment period) without regard to GEP biomarker status."
      },
      {
        "id": "cohort_2",
        "name": "China Cohort",
        "instanceType": "StudyCohort",
        "characteristic": "Approximately 120 Chinese subjects enrolled to meet local regulatory needs, including those from the China extension enrollment period."
      }
    ],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Pembrolizumab Arm - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Pembrolizumab Arm during Screening"
      },
      {
        "id": "elem_2",
        "name": "Pembrolizumab Arm - Initial Treatment Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Pembrolizumab Arm during Initial Treatment Phase"
      },
      {
        "id": "elem_3",
        "name": "Pembrolizumab Arm - Second Course Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Pembrolizumab Arm during Second Course Phase"
      },
      {
        "id": "elem_4",
        "name": "Pembrolizumab Arm - Safety Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Pembrolizumab Arm during Safety Follow-up"
      },
      {
        "id": "elem_5",
        "name": "Pembrolizumab Arm - Survival Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Pembrolizumab Arm during Survival Follow-up"
      },
      {
        "id": "elem_6",
        "name": "Physicians’ Choice Arm - Screening",
        "instanceType": "StudyElement",
        "description": "Treatment period for Physicians’ Choice Arm during Screening"
      },
      {
        "id": "elem_7",
        "name": "Physicians’ Choice Arm - Initial Treatment Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Physicians’ Choice Arm during Initial Treatment Phase"
      },
      {
        "id": "elem_8",
        "name": "Physicians’ Choice Arm - Second Course Phase",
        "instanceType": "StudyElement",
        "description": "Treatment period for Physicians’ Choice Arm during Second Course Phase"
      },
      {
        "id": "elem_9",
        "name": "Physicians’ Choice Arm - Safety Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Physicians’ Choice Arm during Safety Follow-up"
      },
      {
        "id": "elem_10",
        "name": "Physicians’ Choice Arm - Survival Follow-up",
        "instanceType": "StudyElement",
        "description": "Treatment period for Physicians’ Choice Arm during Survival Follow-up"
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 10,
      "cohortCount": 2,
      "elementCount": 10
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Open Label",
        "codeSystem": "USDM",
        "decode": "Open Label"
      },
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "1:1"
      },
      "stratificationFactors": [
        "Tumor histology",
        "Geographic region"
      ],
      "controlType": {
        "code": "Active Control",
        "codeSystem": "USDM",
        "decode": "Active Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "cohortIds": [
        "cohort_1",
        "cohort_2"
      ],
      "therapeuticAreas": [
        "Oncology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Open Label",
        "maskedRoles": []
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "1:1",
        "stratificationFactors": [
          "Tumor histology",
          "Geographic region"
        ]
      },
      "controlType": "Active Control",
      "therapeuticAreas": [
        "Oncology"
      ]
    },
    "arms": [
      {
        "name": "Pembrolizumab Arm",
        "type": "Experimental Arm",
        "description": "Pembrolizumab (MK-3475) 200 mg IV every 3-weeks (Q3W) for up to 35 administrations (approx. 2 years).",
        "isTitration": false,
        "doseEpochs": null
      },
      {
        "name": "Physicians’ Choice Arm",
        "type": "Active Comparator",
        "description": "Investigator’s choice of one of three regimens: Paclitaxel (80-100 mg/m2 on Days 1, 8, 15 of 28-day cycle), Docetaxel (75 mg/m2 Q3W), or Irinotecan (180 mg/m2 Q2W).",
        "isTitration": false,
        "doseEpochs": null
      }
    ],
    "cohorts": [
      {
        "name": "Global Cohort",
        "characteristic": "Approximately 600 subjects enrolled globally (including China during global enrollment period) without regard to GEP biomarker status."
      },
      {
        "name": "China Cohort",
        "characteristic": "Approximately 120 Chinese subjects enrolled to meet local regulatory needs, including those from the China extension enrollment period."
      }
    ],
    "epochs": [
      {
        "name": "Screening",
        "description": "Up to 28 days prior to randomization; includes tumor sample evaluation for PD-L1 and GEP."
      },
      {
        "name": "Initial Treatment Phase",
        "description": "Treatment with Pembrolizumab or Investigator's choice until PD, toxicity, or 35 doses of Pembrolizumab."
      },
      {
        "name": "Second Course Phase",
        "description": "Retreatment with Pembrolizumab for up to 17 additional treatments (approx. 1 year) for eligible subjects who previously achieved CR or completed 2 years of treatment."
      },
      {
        "name": "Safety Follow-up",
        "description": "30 days after end of treatment for AE monitoring; 90 days for SAEs."
      },
      {
        "name": "Survival Follow-up",
        "description": "Follow-up for overall survival until death, withdrawal of consent, or end of study."
      }
    ]
  }
}